Opinion|Videos|November 17, 2026

Choosing Among Emerging Systemic Agents for Vitiligo

With multiple oral JAK inhibitors approaching approval, sequencing decisions and adverse-event management are becoming urgent clinical questions. Dr. Desai and Dr. Hamzavi outline how they select agents and manage risk.

In "Choosing Among Emerging Systemic Agents for Vitiligo," the panel turns to the emerging class of oral therapies and the safety questions they raise.

Dr. Desai frames the choice among emerging oral JAK inhibitors as an embarrassment of riches rather than a simple ranking, noting the field could soon have three options available. He says there is no one-size-fits-all answer and that his own sequencing preferences will be shaped by which agent reaches patients first, since real-world clinical experience matters as much as trial data. His selection process starts with a detailed comorbidity history and an assessment of body-surface area and severity, and he stresses that severity is not defined by extent alone. A patient with only three to five percent body-surface involvement can still be severe if the disease carries heavy psychological burden or affects a high-impact site. He argues strongly against delaying systemic treatment, since waiting only makes lost pigment harder to recover, comparing early intervention to stopping a fire before it spreads.

Dr. Taylor turns the conversation to adverse events, and Dr. Hamzavi explains that the first wave of systemic agents targets the JAK-STAT pathway, with IL-15 inhibitors still in earlier-phase trials behind them. He cautions that safety data drawn from other diseases, such as rheumatoid arthritis or large-vessel vasculitis, may not translate directly to vitiligo patients, who tend to have lower baseline rates of skin cancer, thromboembolic disease, and internal malignancy. Still, he flags real risks clinicians should manage: JAK inhibitors carry thromboembolic risk, so hypercoagulable factors need review, and JAK1 agents specifically raise cardiovascular risk through lipid changes, a risk JAK3 agents do not appear to share. Infection rates in vitiligo trials have largely matched placebo, with the exception of zoster, and he recommends zoster vaccination before starting therapy in patients over fifty. He tailors his agent choice accordingly, favoring lower zoster-risk options with vaccination in older patients and avoiding JAK1 agents in those with cardiovascular risk factors.

Up next, in "The Future of Vitiligo Treatment: A Message to Payers," the panel offers closing thoughts on where vitiligo treatment is headed next.

This video was supported independently by Pfizer.


Related to this article